Skip to main content
OpenTrials
Completed

NCT Number: NCT01819038

Early Renal Replacement Therapy and the Outcome of Acute Kidney Injury

This research project is a prospective study to compare mortality between early renal replacement therapy (RRT) and late renal replacement therapy by using plasma neutrophil gelatinase associated lipocalin (pNGAL) as a tool in decision- making.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

King Chulalongkorn Memorial Hospital

Bangkok, 10330, Thailand

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patient must have given his/her informed and signed consent
  • patients with acute kidney injury in the intensive care ward.

Exclusion criteria

  • The patient refuses to sign the consent
  • The patient is pregnant, parturient, or breastfeeding
  • End stage renal disease
  • Chronic renal failure
  • previous kidney transplant

Treatment and study plan

Continuous Renal Replacement Therapy

Procedure

Primary outcomes

  1. mortality rate

    Time frame: 28 day

Secondary outcomes

  1. ventilator free-days

    Time frame: 28 days

Other outcomes

  1. hemodialysis free-days

    Time frame: 28 days

Sponsors and collaborators

Lead sponsor

Chulalongkorn University

Other

Registry information

Acronym: EarlyRRT

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Mar 27, 2013
Registry last updated
Jan 28, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.